Lifestyle
- Regular exercise
- Adequate sleep
- Stress management
Immunoglobulin G · IgG
IgG quantifies the concentration of immunoglobulin G antibodies in the blood.
Reference ranges may vary slightly based on laboratory standards and methods.
Immunoglobulin G (IgG) is the most abundant type of antibody found in the circulation, playing a crucial role in the body's immune response by identifying and neutralizing pathogens such as bacteria and viruses. IgG is produced by plasma cells and is involved in the secondary immune response, providing long-term protection. Clinically, IgG levels are significant in diagnosing and monitoring various conditions, including autoimmune disorders, infections, and immunodeficiencies. Elevated IgG levels can indicate chronic infections, autoimmune diseases, or liver disease, while low levels may suggest immunodeficiency or protein-losing conditions. In the context of athletic performance and biohacking, IgG's role in immune function is critical, as maintaining optimal immune health is essential for recovery and performance. IgG glycosylation patterns have been studied in relation to aging, with certain glycan profiles associated with inflammaging, a chronic low-grade inflammation linked to aging. Researchers have found that IgG levels can be influenced by various factors, including infections, autoimmune activity, and genetic predispositions. Testing for IgG does not typically require fasting, but levels can be affected by acute infections or recent vaccinations, which should be considered when interpreting results.
Klinische Bedeutung
Elevated IgG levels may indicate chronic infections, autoimmune diseases, or liver disease. Reduced IgG levels can suggest immunodeficiency, protein-losing conditions, or certain genetic disorders.
Progressively rising IgG levels may suggest worsening of chronic infections or autoimmune activity. Retesting is recommended in 4-6 weeks.
Progressively falling IgG levels could indicate improving infection control or potential immunodeficiency.
Re-test Interval
4-6 weeks if outside optimal range
Note:
Consult a healthcare provider before starting any supplementation, especially if underlying conditions are present.
Testing Frequency
Annually for individuals with immune-related conditions or as advised by a healthcare provider.
Current research suggests that reference ranges for immunoglobulin G (IgG) glycosylation patterns in aging and their implications for inflammation modulation remain understudied. Researchers have not yet established optimal targets for IgG biomarkers in conditions like neuromyelitis optica and autoimmune astrocytopathy. Additionally, clinical questions regarding the long-term efficacy of treatments targeting IgG-related disorders and the role of IgG glycosylation in disease progression remain unanswered.
1,059
Total Citations
6
Human/RCT
13.2
Avg. Influence
2025
Latest
Researchers characterized a novel autoimmune central nervous system disorder with glial fibrillary acidic protein (GFAP)-IgG as a biomarker in 102 patients. They found that GFAP-IgG positivity is highly specific for an immunotherapy-responsive autoimmune CNS disorder. The study also noted that the presence of GFAP-IgG in cerebrospinal fluid (CSF) correlates with specific clinical phenotypes.
Researchers found that the glycosylation patterns of Immunoglobulin G (IgG) vary significantly with age and disease states, making it a potential biomarker for general health. They noted that changes in IgG glycosylation can influence immune function and may play a role in disease progression, suggesting its analysis could enhance existing disease biomarkers.
Researchers emphasized the importance of cerebrospinal fluid (CSF) analysis for diagnosing multiple sclerosis (MS), focusing on intrathecal immunoglobulin G (IgG) synthesis. They found that κ-free light chains (FLCs) are a promising new biomarker with high diagnostic accuracy, suggesting their inclusion in future MS diagnostic criteria.
Researchers reviewed high-throughput methods for analyzing Immunoglobulin G (IgG) glycosylation, which is important for understanding its functional relevance in health and disease. They emphasized the need for robust and affordable methodologies to facilitate the discovery of glycan biomarkers in clinical settings.
Researchers reviewed the role of Immunoglobulin G (IgG) glycans in aging, highlighting their potential as biomarkers and molecular effectors. They summarized studies on how IgG glycosylation patterns change with age and discussed the implications of these changes for understanding the aging process and age-related diseases.
Researchers explored the relationship between glycosylation and aging, particularly focusing on immunoglobulin G (IgG) N-glycome changes. They found that agalactosylated IgG glycans may modulate inflammation levels associated with aging, proposing the IgG glycopattern as a potential biomarker for healthy aging.
Researchers reviewed biochemical biomarkers for multiple sclerosis (MS), highlighting the significance of immunoglobulin G oligoclonal bands (OCB) in CSF for diagnosis. They noted that κ-free light chains (FLCs) have shown higher sensitivity and specificity than OCB, suggesting their potential role in MS diagnosis and prognosis.
Researchers summarized the impact of Immunoglobulin G (IgG) glycosylation on tumor immunity and progression. They noted that specific glycosylation modifications correlate with tumor characteristics, suggesting that IgG glycosylation could be a target for improving tumor diagnosis and treatment strategies.
Researchers outlined laboratory diagnosis recommendations for Zika virus infection, emphasizing the detection of ZIKV-specific immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies. They found that combining serologic and molecular testing is crucial for accurate diagnosis, especially in pregnant women.
Researchers reviewed advancements in neuromyelitis optica, focusing on the serum antibody biomarker neuromyelitis optica immunoglobulin G (NMO-IgG). They found that NMO-IgG distinguishes neuromyelitis optica from multiple sclerosis and is now part of new diagnostic criteria. The study also identified aquaporin-4 as the molecular target of NMO-IgG, enhancing understanding of the disease.
Research publications about Immunglobulin G over time
9totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer